Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Perotti

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|February 1, 1989
Evaluation of selective boron absorption in liver tumorsD Chiaraviglio, F De Grazia, A Zonta, et al.
Affari Sociali Internazionali|January 1, 1990
[Migration]W Maccotta, A Perotti, F Thebaut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancerG Grasselli, L Viganò, G Capri, et al.
European Journal of Cancer (Oxford, England : 1990)|February 14, 2004
Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicinC Sessa, A Perotti, E Salvatorelli, et al.
Blood|September 5, 2013
Transcriptional regulation of the Ikzf1 locusToshimi Yoshida, Esther Landhuis, Marei Dose, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2008
Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancerC Sessa, A Perotti, C Noberasco, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2012
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma)P L Zinzani, E Derenzini, C Pellegrini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2009
Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumoursA Perotti, C Sessa, A Mancuso, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|February 1, 1989
Evaluation of selective boron absorption in liver tumorsD Chiaraviglio, F De Grazia, A Zonta, et al.
Affari Sociali Internazionali|January 1, 1990
[Migration]W Maccotta, A Perotti, F Thebaut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancerG Grasselli, L Viganò, G Capri, et al.
European Journal of Cancer (Oxford, England : 1990)|February 14, 2004
Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicinC Sessa, A Perotti, E Salvatorelli, et al.
Blood|September 5, 2013
Transcriptional regulation of the Ikzf1 locusToshimi Yoshida, Esther Landhuis, Marei Dose, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2008
Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancerC Sessa, A Perotti, C Noberasco, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2012
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma)P L Zinzani, E Derenzini, C Pellegrini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2009
Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumoursA Perotti, C Sessa, A Mancuso, et al.
Pageof 2